Verona Pharma meeting its primary objective in its Phase IIa trial evaluating RPL554 as an add-on therapy to tiotropium in COPD patients is extremely encouraging and follows the positive results from all of its clinical trials with a new proprietary suspension formulation of RPL554. The trial demonstrated a statistically and clinically meaningful improvement in lung function and speed of onset with a clear dose response with the 6mg dose. RPL554 continues to demonstrate an attractive profile wit ....
07 Sep 2017
N+1 Singer - Verona Pharma - Positive top-line data from Phase IIa add-on trial to tiotropium
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Verona Pharma - Positive top-line data from Phase IIa add-on trial to tiotropium
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
07 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
Verona Pharma meeting its primary objective in its Phase IIa trial evaluating RPL554 as an add-on therapy to tiotropium in COPD patients is extremely encouraging and follows the positive results from all of its clinical trials with a new proprietary suspension formulation of RPL554. The trial demonstrated a statistically and clinically meaningful improvement in lung function and speed of onset with a clear dose response with the 6mg dose. RPL554 continues to demonstrate an attractive profile wit ....